Aerie Pharmaceuticals Inc logo

AERI - Aerie Pharmaceuticals Inc News Story

$12.61 0.5  4.2%

Last Trade - 07/08/20

Sector
Healthcare
Size
Mid Cap
Market Cap £449.0m
Enterprise Value £394.7m
Revenue £60.8m
Position in Universe 2829th / 6395

BRIEF-Aerie Pharmaceuticals Says Withdrawing 2020 Guidance For Net Revenues And Net Cash Used In Operations

Thu 9th April, 2020 10:01pm
April 9 (Reuters) - Aerie Pharmaceuticals Inc  AERI.O :
    * AERIE PHARMACEUTICALS PROVIDES 2020 COMPANY AND GUIDANCE
UPDATE
ASSOCIATED WITH COVID-19
    * AERIE PHARMACEUTICALS INC - WITHDRAWING ITS 2020 GUIDANCE
FOR
NET REVENUES AND NET CASH USED IN OPERATIONS
    * AERIE PHARMACEUTICALS INC - GUIDANCE WILL BE UPDATED WHEN
THERE
IS CLARITY GOING FORWARD
    * AERIE PHARMACEUTICALS INC - REGULATORY REVIEW IN EUROPE OF
ROCLANDA REMAINS ON TRACK
    * AERIE PHARMACEUTICALS INC - HAS OBSERVED NO DISRUPTIONS TO
DATE
IN ITS SUPPLY CHAIN FOR PRODUCTION OF RHOPRESSA AND ROCKLATAN
    * AERIE PHARMACEUTICALS INC - HOPES TO COMMENCE ITS PHASE 2B
CLINICAL STUDY FOR DRY EYE CANDIDATE AR-15512 BY END OF 2020
    * AERIE PHARMACEUTICALS INC - FROM A PIPELINE PERSPECTIVE,
AERIE'S
EARLY STAGE RETINA IMPLANT TRIALS REMAIN ON TRACK

Source text for Eikon:  ID:nBwcdQL63a 
Further company coverage:  AERI.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.